Celltrion reported Q2 revenue of KRW 1.3 trillion and operating profit of KRW 430 billion, surpassing market consensus by 5% and 8% respectively and marking year-over-year increases of 35.2% and 77.3%. The earnings beat was driven by rapid sales growth of new biosimilar products including Remsima SC, Yuflyma, Truxima, Zymfentra, and Omlyclo, which now account for 58% of total revenue according to Korea Investment Securities estimates. Securities analysts expect the growth momentum to accelerate in the second half with multiple US product launches scheduled and contributions from the Eli Lilly manufacturing facility acquisition beginning to materialize.
Celltrion Reports Q2 Revenue of KRW 1.3 Trillion, Beats Consensus
Celltrion announced on the 3rd that it recorded consolidated Q2 revenue of KRW 1.3 trillion and operating profit of KRW 430 billion. The figures represent year-over-year increases of 35.2% and 77.3% respectively. The operating profit margin rose to the mid-30% range. Revenue exceeded the market consensus average by 5%, while operating profit surpassed expectations by 8%.
New Biosimilar Products Drive 58% of Sales Mix
The strong performance was attributed to the "new product effect" as sales of Remsima SC, Yuflyma, Truxima, Zymfentra, and Omlyclo—the biosimilar of Xolair—expanded rapidly. Korea Investment Securities estimated that new product sales reached 58% of total revenue, pushing the gross profit margin above 62%.
US contract manufacturing organization (CMO) revenue began to be reflected in earnest, and results from the Eli Lilly production facility acquired in December contributed to top-line growth. Celltrion acquired Eli Lilly's biopharmaceutical manufacturing facility in Branchburg, New Jersey, and secured a CMO contract worth approximately KRW 678.7 billion (USD 473 million) from Lilly.
Lee Dal-mi, analyst at Sangsangin Securities, stated, "With the Lilly plant acquisition and CMO contract, approximately KRW 200 billion in annual sales is expected this year, with partial reflection starting from Q2."
Cost ratio improvements are expected to enhance profit margins. Sangsangin Securities projected Celltrion's cost ratio will improve 4.6 percentage points from 40.7% in the previous year to 36.1% this year, resulting in annual operating profit of KRW 1.809 trillion—a 55% increase year-over-year.
Omlyclo US Launch Scheduled for Q4, Multiple Products Entering US Market
The market is focusing on momentum concentrated in the second half. Securities analysts agree that Celltrion's growth pace is accelerating faster than initially expected. Since most new biosimilars launched in the second half of the previous year, their earnings contribution is projected to expand significantly from the second half of this year onward.
In the US market, launches of Steqeyma and Idenzelt are scheduled, which is expected to further amplify the new product effect. Zymfentra is understood to be achieving record prescription volumes in the US.
Expectations for Omlyclo are particularly high. Omlyclo is rapidly expanding market share in Europe where no competing biosimilars currently exist, and growth is projected to steepen after its Q4 US launch. The original drug Xolair's primary indications include chronic idiopathic urticaria, asthma, and food allergies. The drug forms a market worth approximately KRW 5 trillion annually in the US alone, leading to assessments that if substitution effects materialize in earnest, it could become Celltrion's new growth pillar.
CT-P70 and CT-P71 Phase 1 Results Expected in H2
New drug development represents another focal point. Celltrion plans to announce Phase 1 clinical results for c-MET-targeted antibody-drug conjugate (ADC) CT-P70 and Nectin-4-targeted ADC CT-P71 in the second half of this year. Development of next-generation pipelines including autoimmune disease treatment CT-P77 and a triple-fusion protein anticancer drug is also underway, raising the possibility of value revaluation from a biosimilar company to a new drug company.
Securities Firms Adjust Target Prices on Growth Outlook
Securities firms are adjusting Celltrion's target prices. Sangsangin Securities raised its target price to KRW 290,000, reflecting new product-driven profitability improvements and second-half growth. Hyundai Motor Securities also raised its target price to KRW 270,000 based on faster-than-expected earnings growth. Both firms revised earnings estimates upward and assessed that the growth story has become more robust.
Korea Investment Securities, however, set its target price at KRW 260,000, down 12% from the previous level. The firm explained this was not due to earnings concerns but to reflect market conditions. It lowered the applied EV/EBITDA multiple by 17% to reflect recent share price weakness across the biotech sector and the decline in the KRX Healthcare Index, which led to the target price reduction.
Korea Investment Securities actually raised its earnings forecasts for Celltrion for this year and next year. The firm projected Celltrion's revenue and operating profit will reach KRW 5.4068 trillion and KRW 1.8728 trillion respectively this year, representing 30% and 60% growth year-over-year. These figures are 3% higher than previous forecasts.
Wi Hae-ju, analyst at Korea Investment Securities, stated, "Having exceeded the quarterly guidance provided at the beginning of the year for two consecutive quarters, annual results are also highly likely to surpass previous forecasts. However, we slightly lowered the target price due to the overall depressed biotech sector conditions."
FAQ
What were Celltrion's Q2 financial results?
Celltrion reported Q2 revenue of KRW 1.3 trillion and operating profit of KRW 430 billion, exceeding market consensus by 5% and 8% respectively. Revenue increased 35.2% year-over-year while operating profit surged 77.3%.
Why did Celltrion's Q2 operating profit increase 77% year-over-year?
The profit surge was driven by rapid sales expansion of new biosimilar products including Omlyclo, Remsima SC, Yuflyma, Truxima, and Zymfentra, which increased the high-margin product mix to 58% of total sales according to Korea Investment Securities. US CMO revenue from the acquired Eli Lilly facility also contributed to growth.
When will Celltrion launch Omlyclo in the US market?
Celltrion plans to launch Omlyclo, the biosimilar of Xolair, in the US market in Q4 of this year. The product currently has no competing biosimilars in Europe and is rapidly gaining market share.
